Patent 12077587 was granted and assigned to Regeneron Pharmaceuticals on September, 2024 by the United States Patent and Trademark Office.
Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.